Publications

Found 26 results
Filters: Keyword is Antibodies, Neutralizing and Author is Burton, Dennis R  [Clear All Filters]
2013
Gavrilyuk J, Ban H, Uehara H, Sirk SJ, Saye-Francisco K, Cuevas A, Zablowsky E, Oza A, Seaman MS, Burton DR et al..  2013.  Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG.. J Virol. 87(9):4985-93.
Ota T, Doyle-Cooper C, Cooper AB, Doores KJ, Aoki-Ota M, Le K, Schief WR, Wyatt RT, Burton DR, Nemazee D.  2013.  B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates.. J Immunol. 191(6):3179-85.
Lyumkis D, Julien J-P, de Val N, Cupo A, Potter CS, Klasse P-J, Burton DR, Sanders RW, Moore JP, Carragher B et al..  2013.  Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer.. Science. 342(6165):1484-90.
Doyle-Cooper C, Hudson KE, Cooper AB, Ota T, Skog P, Dawson PE, Zwick MB, Schief WR, Burton DR, Nemazee D.  2013.  Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10.. J Immunol. 191(6):3186-91.
Zhou T, Zhu J, Wu X, Moquin S, Zhang B, Acharya P, Georgiev IS, Altae-Tran HR, Chuang G-Y, M Joyce G et al..  2013.  Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies.. Immunity. 39(2):245-58.
Sok D, Moldt B, Burton DR.  2013.  SnapShot: broadly neutralizing antibodies.. Cell. 155(3):728-728.e1.
Pancera M, Shahzad-ul-Hussan S, Doria-Rose NA, McLellan JS, Bailer RT, Dai K, Loesgen S, Louder MK, Staupe RP, Yang Y et al..  2013.  Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.. Nat Struct Mol Biol. 20(7):804-13.
2012
Ota T, Doyle-Cooper C, Cooper AB, Huber M, Falkowska E, Doores KJ, Hangartner L, Le K, Sok D, Jardine J et al..  2012.  Anti-HIV B Cell lines as candidate vaccine biosensors.. J Immunol. 189(10):4816-24.
Burton DR, Poignard P, Stanfield RL, Wilson IA.  2012.  Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses.. Science. 337(6091):183-6.
Ahmed FK, Clark BE, Burton DR, Pantophlet R.  2012.  An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.. Vaccine. 30(5):922-30.
Moldt B, Rakasz EG, Schultz N, Chan-Hui P-Y, Swiderek K, Weisgrau KL, Piaskowski SM, Bergman Z, Watkins DI, Poignard P et al..  2012.  Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo.. Proc Natl Acad Sci U S A. 109(46):18921-5.
Montero M, Gulzar N, Klaric K-A, Donald JE, Lepik C, Wu S, Tsai S, Julien J-P, Hessell AJ, Wang S et al..  2012.  Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane.. J Virol. 86(6):2930-41.
Falkowska E, Ramos A, Feng Y, Zhou T, Moquin S, Walker LM, Wu X, Seaman MS, Wrin T, Kwong PD et al..  2012.  PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.. J Virol. 86(8):4394-403.

Pages